Adma Biologics reported $59.23M in EBIT for its fiscal quarter ending in March of 2026.





Ebit Change Date
Adma Biologics USD 59.23M 3.52M Mar/2026
Alnylam Pharmaceuticals USD 137.59M 108.19M Mar/2026
BioCryst Pharmaceuticals USD 260.38M 230.79M Dec/2025
Minerva Neurosciences USD -4.37M 1.71M Sep/2024
Novavax USD 20.94M 100.32M Dec/2025
Omeros USD -48.15M 7.25M Sep/2023
Takeda JPY -13.62B 271.11B Mar/2026